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At least 17 genomic regions are established as harboring melanoma susceptibility variants, in most instances with genome-wide
levels of significance and replication in independent samples. Based on genome-wide single nucleotide polymorphism (SNP) data
augmented by imputation to the 1,000 Genomes reference panel, we have fine mapped these regions in over 5,000 individuals
with melanoma (mainly from the GenoMEL consortium) and over 7,000 ethnically matched controls. A penalized regression
approach was used to discover those SNP markers that most parsimoniously explain the observed association in each genomic
region. For the majority of the regions, the signal is best explained by a single SNP, which sometimes, as in the tyrosinase region,
is a known functional variant. However in five regions the explanation is more complex. At the CDKN2A locus, for example, there
is strong evidence that not only multiple SNPs but also multiple genes are involved. Our results illustrate the variability in the
biology underlying genome-wide susceptibility loci and make steps toward accounting for some of the “missing heritability.”
Genome-wide association (GWA) studies have been extremely
successful at identifying genomic regions associated with com-
plex diseases and phenotypic traits.1 However, studies often do
not go beyond reporting the most strongly associated geno-
typed single nucleotide polymorphism (SNP) and the best can-
didate gene within the region covered by the association signal.
The reported SNP is unlikely to be the causal variant and does
not necessarily even identify the relevant gene. Thus the
reported SNP is unlikely to characterize the relationship
between genotype and phenotype, and hence may not add
much to the understanding of disease aetiology.
Although GWA studies involve the genotyping of hun-
dreds of thousands of markers across the genome, a variant
not available on the genotyping platform may be more
strongly associated with outcome than the single most signiﬁ-
cant genotyped SNP. Coverage of the region may be greatly
improved without extra genotyping by imputation of ungeno-
typed markers, allowing greater reﬁnement of the association
signal. The genetic information gained by imputation may
help to identity potential causal variants that are in linkage
disequilibrium (LD) with the associated genotyped markers
and improve the selection of genes chosen for denser
What’s new?
In genome-wide association studies, researchers identify genetic variants that frequently associate with a particular disease,
though the variants identified may not contribute to the molecular cause of the disease. This study took a closer look at 17
regions associated with melanoma, fine mapping the regions both in people with melanoma and in healthy controls. Though
single SNPs account for the association in some regions, they found that in a few regions, several SNPs – and possibly multi-
ple genes – contributed to the association signal. These findings illustrate the importance of not overlooking the interaction
between multiple genetic markers when conducting such studies.
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genotyping or sequencing. Furthermore, in some genomic
regions multiple markers may better explain the association
signal, and multiple variants may be independently associated
with the trait. A recent study of the region around the telo-
merase reverse transcriptase gene TERT, within which there
are SNPs associated with a number of cancers including mel-
anoma, reported multiple independent SNP associations with
both telomere length and breast cancer risk.2 For these rea-
sons, disease risk estimates based solely on the single
reported SNP may not adequately reﬂect the contribution of
the region to the heritability and aetiology of disease.
Recent GWA studies of melanoma susceptibility,
pigmentation-related phenotypes and nevi have led to the
discovery and conﬁrmation of a number of genomic regions
associated with risk of melanoma.3–8 Association signals for
these regions vary greatly, both in their strength and in the
breadth of region showing association. For instance, associ-
ated SNPs in the 21q22.3 region (near MX2) span <100 kb,
whereas associated SNPs in the 20q11.2-q12 region (near
ASIP) cover more than 1 Mb. This variation may be due
largely to differing patterns of LD around a single variant or
could be indicative of a more complex arrangement of func-
tional variants. We have previously shown in a melanoma
case-control study that ﬁne mapping of an association signal
through imputation can help to implicate a gene (MC1R)
with known functional relevance,9 despite the initial associa-
tion signal spanning a number of candidate genes, the signal
here being due to multiple less common loss-of-function
variants.
The aim of this study is to reﬁne the association signal
in each of the 17 genomic regions previously shown to be
associated with melanoma risk using a large case-control
dataset.
Material and Methods
Study population
Cases for the GenoMEL GWA study of melanoma were pref-
erentially selected to have a family history of melanoma, mul-
tiple primary tumors or an onset before 40 years of age,
mainly from centers across Europe. In all 2,744 cases and
1,834 controls from Phases 1 or 2 of the study were included
in this analysis (see Supporting Information Table 1). An
additional 5,857 population-based controls were obtained
from the Center National de Genotypage in France or the
Wellcome Trust Case Control Consortium (WTCCC) in the
UK. Additional cases were obtained from two sources. First,
1,238 cases from the Leeds melanoma cohort were included;
this is a population-based study of incident cases diagnosed
between September 2000 and December 2006 from a geo-
graphically deﬁned area of Yorkshire and the Northern
region of the UK.10 Second, 1,392 cases were included from
the Studies of Epidemiology and Risk Factors in Cancer
Heredity (SEARCH) series of population-based studies in
Eastern England.11 This resulted in a combined sample set of
5,374 cases and 7,691 controls for the analysis after quality
control (QC) described below.
Genotyping
GenoMEL Phase 1 samples were genotyped on the Illumina
HumanHap300 BeadChip version 2 duo array and the Illu-
mina HumanCNV370 array. GenoMEL Phase 2 samples were
genotyped on Illumina Human610-Quad array. The addi-
tional UK cases were genotyped on the Illumina HumanOm-
niExpressExome BeadChip. The WTCCC samples were
genotyped on the Illumina HumanHap 1.2 M array, but only
SNPs that were also on either the HumanHap300 or
Human610 array were retained for imputation. Samples and
SNPs on the HumanOmniExpressExome array were subjected
to the same stringent QC as the GenoMEL GWA datasets,
previously described in detail.4,5 Brieﬂy, samples were
excluded for any of the following reasons: (i) a call-rate of
<97% (of the total number of SNPs on the chip); (ii) evidence
of non-European origin from principal components analysis;
(iii) sex as ascertained by genotyping not matching reported
sex; (iv) evidence of ﬁrst degree relationship or identity with
another sample; (v) recommendation to be excluded by the
WTCCC (for WTCCC samples only). To ensure high quality
imputation, very stringent QC measures were applied within
each genotyped array; SNPs could therefore be excluded from
just a subset of our entire sample. SNPs were excluded for
any of the following reasons: (i) Hardy–Weinberg equilibrium
p value <1024 in controls; (ii) call-rate <97%; (iii) recom-
mendation for exclusion by the WTCCC (for WTCCC sam-
ples only); (iv) minor allele frequency (MAF)< 0.03.
Imputation
Imputation was conducted separately on each array using
IMPUTEv212 with the 1000 Genomes Phase 1 integrated var-
iant set as reference panel (March 2012 release, excluding
SNPs with MAF< 0.001 in CEU European samples). Imputa-
tion was constrained to a 2 Mb region (6 Mb for the
20q11.2-q12 region around ASIP) centered on the reference
SNP. Only those SNPs that were either (i) genotyped on all
arrays (Type A); (ii) imputed with an INFO score 0.8 on
all arrays (Type B); or (iii) imputed with an INFO score
0.5 (but not 0.8) on all arrays and with a MAF 0.03
(Type C) were retained for analysis.
Statistical analysis
A total of 17 regions were analyzed, all of which have been
reported to include a SNP associated with melanoma risk, in
most instances with a genome-wide level of statistical signiﬁ-
cance and replication in independent samples (Table 1). For
convenience the regions will be referred to by the name of a
likely candidate gene.
For single SNP analyses of association with melanoma,
imputed genotypes were analyzed as expected genotype counts
based on the posterior probabilities (gene dosage) using logistic
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regression implemented in SNPTEST2,18 assuming an additive
model, with geographical region (UK/Netherlands, France,
Spain, Scandinavia, Italy, Poland, Israel) as a covariate. We
have previously shown that adjusting for region adequately
adjusts for population stratiﬁcation and that including princi-
pal components brings no improvement.4 No further analysis
was conducted for any region where no SNP reached a
p value<1025 in this analysis. For other regions the SNP-by-
SNP analysis was repeated adjusting for the most signiﬁcant
SNP in the region by including this in the logistic regression
model.
Each of the regions was narrowed down to the interval cov-
ering 500 kb on either side of any SNP with p value< 1026 in
the initial single SNP unadjusted analysis. Penalized logistic
regression is an effective method for the simultaneous analysis
of large numbers of correlated variables and was therefore used
to jointly analyze all SNPs in each of these narrower intervals.
The analysis was carried out using Hyperlasso,19 which imple-
ments a Bayesian-inspired penalized maximum likelihood
approach with a normal-exponential-gamma (NEG) prior.
Genotypes were standardized, and geographical region was
adjusted for as before. Model parameters were set to control
the type-I error at 1024, with the shape parameter ﬁxed at
0.05,19 and 100 iterations were run for each region. Each itera-
tion searches for the model with maximum likelihood, but the
model may differ between iterations because of the stochastic
nature of the order in which variables are considered for inclu-
sion in the model. Each model selected was analyzed further
using logistic regression (with no penalization). For interpreta-
tion, models were considered to be statistically equivalent if the
SNPs included were in complete or very strong LD (based on
the correlation coefﬁcient r2 between estimated SNP dosages).
For comparison, ﬁve regions (SLC45A2, TYR, ASIP, TERT,
and CDKN2A) with different features (see Results) were also ana-
lyzed with alternative penalty functions (lasso and elastic net)
using the glmnet function20 in R (version 2.15.2, R Foundation for
Statistical Computing, Vienna, Austria, 2012). For this analysis, to
aid interpretation LD-based pruning using PLINK21 was used to
remove markers that were very highly associated (r2> 0.95) prior
to the penalized regression analysis. The penalty for each term in
these analyses is of the form k (a|b|1 (12a) b2), where b is
the coefﬁcient for that term; for lasso, a5 1, and for the elastic
Figure 1. Association signals for the 13 regions analyzed in the fine mapping Manhattan plots displaying the strength of association with
melanoma risk (2log10 p) from the single SNP analysis versus chromosomal position (Mb). The colors indicate the imputation quality:
black5 fully genotyped (a), red5 imputed with a minimum INFO score0.8 (b) and green5 imputed with a minimum INFO score 0.5 but
<0.8 and MAF >3%.
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net we used a5 0.5. The multiplier k was chosen by cross-
validation implemented in glmnet. As before, geographical region
was included in each model and genotypes were standardized.
Results
About half of all SNPs (genotyped or imputed) were retained
for analysis after post-imputation SNP QC (ranging from
37% in OCA2 to 55% in PARP1); most exclusions were on
the basis of poor quality of imputation (Supporting Informa-
tion Table 2).
SNP-by-SNP analyses
For three regions (IRF4, TYRP1 and OCA2), no SNP was
associated at p< 1025 in these data; these regions were not
analyzed further after the initial single SNP analysis. In addi-
tion MC1R has been analyzed separately,9 so results are only
presented for the remaining 13 regions.
For two of the regions (SLC45A2 and FTO), the most sig-
niﬁcantly associated SNP in our data was the same as the top
SNP reported in the reference paper. For each of the remain-
ing regions, a more signiﬁcantly associated SNP was found
(Table 1).
Figure 1 shows Manhattan plots for each of these 13
regions after imputation. The regions near SLC45A2, FTO
and MX2 all exhibit very narrow association signals,
whereas others have signals that encompass several genes,
the widest of these being the ASIP region covering several meg-
abases. When adjusting for the most signiﬁcant SNP, the
TERT, CDKN2A and CCND1 regions have a clear secondary
signal reaching at least 1025 (Supporting Information Fig. 1).
Hyperlasso analyses
Single variant regions. In the Hyperlasso analyses, the effect
on disease risk was best described by a single-SNP model for
8 regions (ARNT, PARP1, CASP8, SLC45A2, TYR, ATM, FTO
and MX2); for each of these regions a single-SNP model was
selected in at least 89% of the iterations. For the remaining
few iterations a 2-SNP model was selected. When a single-
SNP model was selected, the SNP was almost always either
the most signiﬁcant SNP from the single SNP analysis (see
Table 1) or one in strong LD with it (almost always r2> 0.9,
Supporting Information Table 3).
For the ARNT region, the SNPs selected in the model
were located within the ARNT gene in 90% of the iterations.
The most strongly associated SNP in the region is rs3768013,
which was selected in 13 of the 100 iterations. Another SNP,
rs7514004, in almost complete LD with this (r25 0.99) was
selected slightly more frequently (16 times), and 8 other
SNPs were selected in different iterations, all also in strong
LD (r2 0.98 for 7 of them, r25 0.92 for one). For the
PARP1 region only 6 out of 100 iterations selected a SNP
actually located in the PARP1 gene; otherwise a SNP located
Table 2. SNPs selected in models for the regions showing evidence for multiple independent associations
Single SNP result
Logistic regression of
multiple variant models
Region SNP name Position Mapped gene Allele
Allele
frequency OR p value
r2 with
top SNP OR p value
R2 for
melanoma
risk
TERT rs7705526 1285974 TERT A 0.332 1.13 2.9 3 1025 0.09 1.09 0.026 0.46
rs2736099 1287340 TERT A 0.374 1.12 6.6 3 1025 0.14 1.09 0.025
rs1801075 1317949 intergenic C 0.172 1.23 2.7 3 10210 0.51 1.08 0.050
rs2447853 1333077 CLPTM1L G 0.468 1.20 5.7 3 10212 Top SNP 1.18 1.3 3 1027
CDKN2A rs869330 21804617 MTAP G 0.513 0.81 3.9 3 10216 Top SNP 0.81 8.0 3 10216 0.65
rs3088440 21968159 CDKN2A A 0.089 1.21 2.0 3 1025 0.03 1.13 0.014
rs3731204 21984661 CDKN2A C 0.148 0.81 2.2 3 1028 0.03 0.84 8.1 3 1026
rs1011970 22062134 CDKN2B-AS1 T 0.166 1.17 2.3 3 1026 0.02 1.09 0.033
CCND1 rs2290419 68919649 intergenic G 0.057 0.78 2.1 3 1025 0.03 0.76 7.2 3 1026 0.37
rs623110 69308897 intergenic T 0.314 1.13 1.3 3 1025 0.35 1.07 0.015
rs12422135 69378736 intergenic A 0.409 1.18 3.5 3 10210 Top SNP 1.15 3.1 3 1027
ASIP rs74325991 32547380 intergenic G 0.490 1.18 8.8 3 1028 0.38 1.11 0.0025 0.31
rs6059655 32665748 RALY A 0.086 1.33 2.1 3 10211 Top SNP 1.26 4.6 3 1027
For each region the model with the greatest number of SNPs in shown after 100 iterations of Hyperlasso. Two different 2-SNP models occurred for
ASIP, both include rs6059655 with either rs74325991 (presented here) or rs6088372 (not shown). The ORs (odd ratios) for the stated allele and p
values are presented for the results from the single SNP analysis and when including all listed SNPs at that locus. The LD (r2) with the most signifi-
cant SNP in this study (Top SNP) is estimated from the correlation coefficient. The R2 for percentage of variation explained in melanoma risk is given
for including all listed SNPs at that locus.
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near the 50 end was selected. Across all iterations, 28 different
SNPs were selected, but all were in very strong LD with the
top SNP rs1858550 (r2 0.97). Similarly, for the CASP8
region, only 17% of the iterations converging to a single-SNP
model selected a SNP in CASP8, with the majority selecting a
SNP in the neighboring gene AL2CR12. The top SNP
rs2349073 was selected most frequently (13 iterations), but
others were similarly frequent and all were in strong LD
(r2 0.94). Only one SNP was selected, in all 100 iterations,
for the SLC45A2 region, this being the previously reported
missense SNP rs16891982. This SNP was also selected using
either the lasso or elastic net penalty. Similarly, the missense
SNP rs1126809 was selected in 44% of the single-SNP models
for the TYR region; in most other iterations an alternate SNP
in LD with this was selected (r2 0.93 in all but 9 iterations,
r2 0.89 otherwise). Using the alternative penalty functions
also resulted in selection of rs1126809. For the ATM region,
in 82 of the 100 iterations a SNP in the ATM gene itself was
selected; although 15 different SNPs were selected, all were in
almost complete LD with the top SNP rs4753835 (r2 0.98).
Only three distinct SNPs were selected for the FTO region,
all in the FTO gene; one was the top SNP rs12596638, and
the other two were in almost perfect LD with this (r2 0.99).
In the MX2 region the top SNP rs443099, or one of ﬁve
other SNPs within the MX2 gene in almost perfect LD
(r2 0.98), was selected in 81% of the iterations converging
on a single-SNP model. For all but one of the remaining iter-
ations, rs390789, a SNP in weaker LD (r25 0.86) and not in
MX2, was selected.
Possible multiple variant region. For the PLA2G6 region a
single-SNP model was selected in 66 iterations (Supporting
Information Table 4), the single SNP being either the top
SNP rs3891103 or one in moderate to strong LD with this
(r2 0.82). In other iterations 2-SNP models were selected
involving SNPs both of which were reasonably strongly asso-
ciated with rs3891103 (r2 0.59, usually much higher). In
most models, both SNPs were located in the PLA2G6 gene.
The results are not as clear-cut as for the above single-SNP
regions; a possible explanation is that a single causal SNP
exists in the region that is not in very strong LD with any
single genotyped or imputed SNP.
Regions showing evidence of multiple independent variants.
Hyperlasso gave a variety of models for the ASIP gene (Table
2, Supporting Information Table 5). Most of these reduce to
Figure 2. Regions showing evidence of multiple independent signals Manhattan plots displaying the strength of association with melanoma
risk (2log10 p) from the single SNP analysis versus chromosomal position (Mb). The colored diamonds indicate the SNPs selected by
Hyperlasso. Those of the same color are in strong LD with r20.80 and correspond to the colored blocks in Supporting Information Tables
5–8. Shaded regions show the position of the genes in the region. (a) ASIP (b) TERT (c) CDKN2A (d) CCND1. C
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two different 2-SNP models occurring with similar frequency.
Both models include rs6059655 in RALY (or a SNP in almost
complete LD, r2 0.98, blue diamonds in Fig. 2a), the other
SNP being either rs6088372 also in RALY (green diamond)
or rs74325991 (red diamond) which is not located in a gene.
Using the alternative penalties, the 2-SNP model including
rs6059655 and rs6088372 was selected.
For all three of the regions (TERT, CDKN2A and CCND1)
that showed strong evidence of further association when
adjusting for the top SNP (Supporting Information Fig. 1),
Hyperlasso selected multiple variant models in all iterations.
Either 3- or 4-SNP models were selected to explain the
signal in the TERT region (Table 2, Supporting Information
Table 6). When taking LD into account, these reduced to two
distinct 3-SNP models (selected in 33 and 12% of iterations)
and one 4-SNP model (55%). The most commonly selected
3-SNP model includes 2 SNPs in the TERT gene (rs7705526
and rs2736099, r25 0.60, D05 0.60 between them, green and
orange diamonds in Fig. 2b) and the top single SNP
rs2447853 (or one in almost complete LD with this) in the
neighboring CLPTM1L gene (red diamonds in Fig. 2b). The
LD between rs2447853 and the 2 SNPs in TERT was
r25 0.09, D05 0.11 for rs7705526 and r25 0.14, D05 0.18
for rs2736099. When regressing melanoma case/control status
on these 3 SNPs, the signal at CLPTM1L becomes stronger
than in the single-SNP analysis (p5 5.5 3 10214). The 4-
SNP model was equivalent to this 3-SNP model, but with an
extra SNP, rs1801075, which lies between TERT and
CLPTM1L, or a SNP in strong LD with this, which includes
SNPs within CLPTM1L (blue diamonds in Fig. 2b). This 4-
SNP model was selected using the alternative penalty func-
tions. The imputation quality was noticeably poor around the
TERT gene; only 29% of variants in the gene (from 1,000
Genomes) are included in the analysis, compared with 50%
across all regions, and 64 of the 78 SNPs that are included
are relatively poorly imputed (Type C) SNPs.
The signal in the CDKN2A region is explained in most iter-
ations by a particular 3-SNP (31 iterations) or 4-SNP model
(54 iterations) (Table 2, Supporting Information Table 7). All
these models included the top SNP rs869330, which is in
MTAP, or a SNP in strong LD with this (blue diamonds in Fig.
2c). There was almost no change in the OR and p value for this
SNP when adding the other 2 SNPs in the 3-SNP model in a
logistic regression analysis. The other 2 SNPs in the model also
gave reasonably strong signals in the multiple logistic regres-
sion analysis. These were located in CDKN2B-AS1 or CDKN2A
(rs3088440 or a SNP in strong LD with this, p< 1024, green
diamonds in Fig. 2c) and CDKN2A (rs3731204 or a SNP in LD
with this, p< 1025, red diamonds in Fig. 2c). The LD between
rs869330 and the other 2 SNPs was r25 0.03 for both
rs3088440 and rs3731204 (D0< 0.07). The LD between
rs3088440 and rs3731204 was r25 0.12, although D05 0.94:
the minor allele for rs3088440 hardly ever occurs with the
minor allele of rs3731204. The 4-SNP model was equivalent to
the 3-SNP model with an additional SNP, rs1011970 or a
proxy, in CDKN2A-AS1 (orange diamonds in Fig. 2c). The
remaining 15 iterations converged on 3-, 4- or 5-SNP models,
which were similar (usually including all the SNPs from the 3-
SNP model). Using the lasso penalty, a 6-SNP model was
selected, including the 4 SNPs in the above 4-SNP model, plus
an additional 2 SNPs from among those highly correlated with
the top SNP rs869330 (blue diamonds in Fig. 2c).
The most frequent model selected for the CCND1 region
(65 iterations) was a 2-SNP model with neither SNP located
in a gene (Table 2, Supporting Information Table 8, Fig. 2d).
The models included the top SNP rs12422135 (p< 1029) or
a proxy, all of which were around 80 kb from CCND1 (red
diamonds in Fig. 2d). The second SNP in the model was
rs2290419 (p< 1025) located distal to MYEOV (green dia-
mond in Fig. 2d). These SNPs are not in LD with one
another (r25 0.03, D05 0.12). In 20 iterations a third SNP
was also selected (rs623110 or rs486564, r25 1.0, blue dia-
mond in Fig. 2d). In the remaining 15 iterations, alternative
3- or 4-SNP models were selected, all of which were equiva-
lent to one of these two models plus one additional SNP.
Improvements in explanatory power. For each region the
percentage of variance in melanoma risk explained by the
reported SNP and the top SNP from this study is shown in
Table 1. If we assume the SNPs contribute additively to risk,
the 13 SNPs studied in detail are estimated to explain 2.4%
of the variance in risk based on the reported SNP, rising to
2.8% if we use the top single SNP based on imputation in
this study. Hence the improvement is modest (17%), and will
be partly driven by over-ﬁtting; the largest single improve-
ment is for ASIP, where the estimate doubles from 0.13 to
0.26%. For the 3 clearly more complex regions, the percent-
age of variance explained by the models in Table 2 compared
with the best single-SNP model increases by 70% (70% for
TERT, 71% for CDKN2A and 68% for CCND1).
Discussion
We have reﬁned the association signals for regions that have
been previously associated with melanoma, using a pragmatic
statistical approach that includes adjusted analyses and penal-
ized logistic regression. We have shown that the complexity
of the association signal within a speciﬁc genomic region
ranges from those regions best explained by a single variant
to those that can only be explained by 3 or 4 variants. The
evidence for multiple independent signals is strong: in three
regions there is a secondary signal reaching p< 1025 after
conditioning on the most signiﬁcant SNP, equivalent to a
Bonferroni correction for 5,000 independent tests in the
region, and these results are borne out by the Hyperlasso
analysis. It is possible that even independent signals represent
a haplotypic effect, although we saw little evidence of haplo-
typic effects from the SNPs in the multiple variant regions. It
is becoming increasingly clear that multiple independent
causal variants may contribute to disease susceptibility at a
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single locus.2 Despite this, statistical approaches are some-
times applied to ﬁne mapping that presuppose the existence
of a single causal variant in a region.22,23
We found strong evidence that a single SNP explains the
association signal in 8 of the 13 regions analyzed here:
ARNT, PARP1, CASP8, SLC45A2, TYR, ATM, FTO and MX2.
For two of the regions (SLC45A2 and TYR), the likely casual
variants are known. The SNP rs16891682 in SLC45A2 was
the only SNP selected by Hyperlasso and was also detected
using other penalty functions; this SNP would likely be iden-
tiﬁed by any reasonable method. The SNP rs1126809 in TYR
was selected using lasso/elastic net and about half of the time
using the Hyperlasso method; the remaining iterations all
converged on a single-SNP model where the SNP selected
was in reasonably strong LD with rs1126809 (r2 0.89). For
the other single-variant regions identiﬁed, although no one
SNP was selected much more frequently than the others, this
was largely due to the inability of any statistical method to
distinguish between almost perfectly correlated variables. The
evidence from analysis of these regions suggests that either
the most strongly associated SNP or one in very strong LD
with it is the most likely explanation of the association signal;
bioinformatic analysis of this relatively small set of SNPs can
now be used to suggest the most promising candidates for
functional investigation.
More complex models were clearly needed to explain the
signals for the regions near TERT, CDKN2A and CCND1.
Interestingly all three of these regions have previously been
reported as harboring multiple risk variants for other diseases
or traits. Independent associations have previously been
reported in TERT for breast cancer and telomere length.2 The
telomere associations partially concur with our model for mel-
anoma; the SNPs associated with telomere length are
rs7705526, the SNP indicated by a green diamond in Figure 2b,
and rs2736108, which is only nominally associated with mela-
noma in our analysis (p5 0.008). Our reported second SNP in
TERT, rs2736099 (orange diamond), is in only moderate LD
with rs2736108 (r25 0.49, D05 0.60), although both are
strongly associated with telomere length in univariate analysis
(p< 1025 in Bojesen et al.2). The TERT SNP alleles associated
with longer telomeres are associated with higher risk of mela-
noma. In addition our most signiﬁcant SNP in the region was
in the neighboring CLPTMIL gene; SNPs in this gene show no
clear association with either telomere length or breast cancer.
We found 3 strong independent signals in the 9p21
region, the strongest being in MTAP, with secondary peaks
in the region containing CDKN2A and CDKN2B-AS1. The
variant rs10811656, associated with coronary artery disease
(CAD),24,25 is peripheral to this region (at 22.12 Mb in the
CDKN2B-AS1 locus, Fig. 2c). The interval around rs10811656
has been studied using chromatin conformation capture in
human vascular endothelial cells26 and shown to physically
interact with both the CDKN2A/B locus and MTAP. This
complex region is clearly of major signiﬁcance in a number
of diseases.
French et al.27 found evidence for 3 distinct signals in the
CCND1 region in relation to oestrogen-receptor-positive
breast cancer. Although different SNPs to ours were identi-
ﬁed, their signals were between 69.32 and 69.38 Mb (Build
37), which is roughly the region spanned by two of the three
signals in our model (blue and red diamonds in Fig. 2d).
Although this region is itself intergenic, on the basis of func-
tional studies these authors conclude that CCND1 is the
likely target gene for the variants identiﬁed.
Here we have employed penalized regression with a NEG
prior to ﬁne map these loci. This choice of prior was moti-
vated by its sharp peak at zero, which shrinks the regression
coefﬁcients strongly when they are close to zero, leading to
sparse models. In a comparison of penalized logistic regres-
sion methods with different penalties, single locus analysis
and stepwise regression, Ayers and Cordell28 showed that the
NEG gave the best overall performance and did not suffer
from limitations on the number of markers being considered.
Reassuringly we found broadly similar results when using a
lasso or elastic net penalty function, although where there
were differences these latter methods seemed to favor models
with larger numbers of SNPs, which were then not signiﬁcant
in the full model using classical logistic regression.
A major limitation of statistical ﬁne mapping based on
imputation is that about half of all possible variants (as iden-
tiﬁed by 1,000 genomes) are dropped because they cannot be
reliably imputed, at least with the density of genotyping used
in our study and after strict QC. There is therefore a need to
more densely genotype, or preferably sequence, parts of these
regions to follow up these analyses. The analysis presented
here helps to prioritize which of the associated loci require
further investigation and, within these, to narrow down the
regions to be sequenced.
We found a substantial (70%) improvement in the pro-
portion of variance in melanoma risk explained by multiple
SNP models compared with single SNPs in selected regions,
although overall the proportion of variance explained by all
loci is only modestly increased. This has been explored in
other traits,29 showing an average increase of 17% in the pro-
portion of variance explained using regression-based analysis
of jointly signiﬁcant markers compared with single variants
at each locus.
Statistical ﬁne mapping does not in itself identify the
causal SNP(s) but it does take us closer to achieving this goal
by narrowing down the number of SNPs to be considered for
further investigation. In all but the very simplest regions
(SLC45A2 and TYR), where coding variants explaining the
signal have been previously identiﬁed, ﬁne mapping must be
followed up using bioinformatics and experimental
approaches. Methods to identify and follow up non-coding
functional variants have recently been reviewed,30 with sug-
gestions of bioinformatics database searches, application of in
silico tools and a range of molecular experimental techniques
that can take the process forward to identify the causal
mechanisms.
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